Rabbani Syed | Pharmaco-Oncology | Innovative Research Award

Innovative Research Award

Rabbani Syed
King Saud University, Saudi Arabia

Rabbani Syed
Affiliation King Saud University
Country Saudi Arabia
Scopus ID 35751491100
Documents 95
Citations 1,703
h-index 21
Subject Area Pharmaco-Oncology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4695-0645

The Innovative Research Award recognizes research activity that contributes to the development of new knowledge, methodologies, or applications within a defined academic discipline. This profile presents the available research information associated with Rabbani Syed of King Saud University, Saudi Arabia, in the context of the International Research Awards on Oncology and Cancer Research.

Abstract

This academic recognition profile documents the supplied research information of Rabbani Syed, affiliated with King Saud University in Saudi Arabia. The researcher is associated with the subject area of Pharmaco-Oncology and has been proposed in connection with the Innovative Research Award. The available bibliometric information includes 95 documents, 1,703 citations, and an h-index of 21. These indicators offer a measurable description of scholarly activity but do not, by themselves, establish the originality or practical effectiveness of individual studies. Further evaluation requires examination of publications, research methods, and documented contributions.

Keywords

Keywords: Innovative Research Award, Rabbani Syed, King Saud University, Saudi Arabia, Pharmaco-Oncology, cancer research, oncology, pharmaceutical research, bibliometrics, scholarly publications, therapeutic research, research recognition.

Introduction

Pharmaco-Oncology encompasses research involving medicines, drug mechanisms, therapeutic development, and pharmacological strategies relevant to cancer care. Innovation in this field may involve the discovery of candidate compounds, investigation of drug responses, improvements in drug-delivery systems, or the evaluation of treatment-related biological mechanisms. Research recognition in this area requires consideration of the scientific question, methodological rigor, reproducibility, and potential relevance to oncology. [2]

Research Profile

Rabbani Syed is identified in the supplied information as a researcher affiliated with King Saud University, Saudi Arabia. The provided Scopus author identifier is 35751491100, while the ORCID identifier is 0000-0003-4695-0645. The supplied profile statistics indicate 95 documents, 1,703 citations, and an h-index of 21. These figures should be interpreted with reference to the date of retrieval and the specific author record. [1]

Research Contributions

The supplied subject classification places the researcher within Pharmaco-Oncology. However, detailed information about specific research projects, experimental findings, patented technologies, clinical investigations, or methodological innovations has not been provided. Consequently, individual contributions cannot be independently described in detail. A comprehensive assessment would examine the originality of the research questions, the quality of the evidence, and the relevance of reported findings to oncology and pharmaceutical science. [3]

Publications

The supplied information reports a total of 95 documents associated with the researcher’s academic record. A complete publication list, including article titles, journals, publication dates, co-authors, and digital object identifiers, was not supplied for this profile. The Scopus author record may provide a starting point for examining indexed publications and related citation information. Publication-level verification is necessary before attributing specific scientific findings or research achievements.

Research Impact

The reported citation count of 1,703 and h-index of 21 provide quantitative indicators of the researcher’s documented scholarly visibility. Citation measures can assist in describing patterns of academic attention, but they may be influenced by publication age, disciplinary practices, collaboration patterns, and database coverage. They should therefore be considered alongside qualitative evidence, including research reproducibility, scientific influence, and documented applications. [4]

Award Suitability

The Innovative Research Award is associated with research that demonstrates originality and meaningful advancement within a relevant field. The supplied affiliation, subject area, publication count, citation count, and h-index provide contextual information for an academic review. A formal award assessment should additionally consider the nominee’s documented innovations, supporting publications, research significance, and compliance with the event’s eligibility criteria. The available information alone does not establish the outcome of an award evaluation.

Conclusion

Rabbani Syed is identified in the supplied data as a King Saud University researcher working in the subject area of Pharmaco-Oncology. The reported record includes 95 documents, 1,703 citations, and an h-index of 21. These metrics summarize selected aspects of scholarly activity. Further information about research innovations, individual publications, and documented scientific outcomes would be required to develop a more comprehensive academic assessment in relation to the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Rabbani Syed, Author ID 35751491100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=35751491100
  2. National Cancer Institute. (n.d.). Drug therapy and cancer treatment research. National Cancer Institute.https://www.cancer.gov/about-cancer/treatment/types
  3. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.https://doi.org/10.1158/2159-8290.CD-21-1059
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  5. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.https://orcid.org/0000-0003-4695-0645

Dr. Michele Moreau – Oncology Therapeutics and Novel Approaches –  Best Researcher Award

Dr. Michele Moreau - Oncology Therapeutics and Novel Approaches -  Best Researcher Award

Johns Hopkins University - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS

Michele Moreau's academic journey began with a Bachelor of Science (B.S.) in Physics from the University of Kentucky in May 2009. Following this foundational degree, Michele pursued a Master of Science (M.S.) in Applied Physics from the Physics Department at the University of Massachusetts Boston, graduating in May 2012. Building upon this, Michele achieved another M.S. in Medical Physics from the Radiological Sciences Department at the University of Massachusetts Lowell in May 2022. These early academic pursuits set the stage for Michele's specialization in the field of biomedical engineering and biotechnology.

PROFESSIONAL ENDEAVORS

During Michele Moreau's academic journey, she served as a Teaching and Research Assistant at the University of Massachusetts Lowell from 2014 to 2023. Her role involved teaching an Introductory Physics Lab course and grading lab reports and quizzes. Furthermore, Michele completed a 6-month internship focused on developing a platform for catalyzing collaborative global Cancer Care Education and Research (CaRE). This initiative aimed to enhance Access to Medical Physics Education and Research Excellence (AMPERE), showcasing her commitment to global health initiatives.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPEUTICS AND NOVEL APPROACHES

Michele Moreau's primary research focus revolves around biomedical research in cancer therapy. As a Graduate Research Trainee from 2015 to 2023 at prestigious institutions such as Harvard Medical School, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Johns Hopkins School of Medicine, Michele specialized in engineering solid and liquid formulations of smart radiotherapy biomaterials. Her expertise encompasses a wide range of techniques and methodologies, including:Engineering Smart Radiotherapy Biomaterials,Monolayer and 3D Cell Culture etc.,

IMPACT AND INFLUENCE

Michele Moreau's research contributions have the potential to revolutionize cancer therapy by improving the effectiveness of in-situ treatment of tumor masses. Her work on smart radiotherapy biomaterials and associated techniques could significantly enhance the precision and efficiency of cancer treatments, benefiting countless patients worldwide.

ACADEMIC CITES

Michele's research findings and contributions to the field of biomedical engineering and biotechnology have likely been cited in various academic publications, journals, and conferences. Her collaborations with esteemed institutions and her focus on cutting-edge research topics make her a notable figure in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Michele Moreau is expected to be conferred with a Ph.D. in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell in August 2023, her legacy in the field is already taking shape. Her multidisciplinary approach to cancer therapy, combining physics, engineering, and biology, paves the way for future advancements in the field. Michele's dedication to improving cancer treatments and her commitment to global health initiatives highlight her potential to leave a lasting impact on biomedical research and patient care.

NOTABLE PUBLICATIONS

Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment. 2024

Pre-Clinical Investigations of the Pharmacodynamics of Immunogenic Smart Radiotherapy Biomaterials (iSRB). 2023

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination. 2023

Polydopamine Nanomaterials for Overcoming Current Challenges in Cancer Treatment. 2023

Phytoradiotherapy to enhance cancer treatment outcomes with cannabidiol, bitter melon juice, and plant hemoglobin. 2023